Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
2023-505169-10-00Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Sep 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and indolent lymphoma, sponsored by Kite Pharma. Started Sep 2023; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)indolent lymphoma
Beyond the preview
Go deeper on 2023-505169-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505169-10-00.